EndPoints Webinar 2022: Why Oncology Needs More Than MRD
Personalis
11/16/22, 3:00 PM
America/Chicago UTC -5
Description
Stephane Mouradian, PhD
Senior Vice President, Business Development and Marketing
Personalis, Inc.
November 16, 2022 | 12:00 PM – 1:00 PM EST
Why Oncology Needs More Than MRD
In parallel with the evolution of cancer therapies over time, the field of molecular diagnostics continues to mature, bringing innovative solutions to precision medicine. The value of using molecular residual disease (MRD) to monitor a patient’s journey post-diagnosis has demonstrated value in oncology, but is this tool sufficient for clinicians to make informed treatment decisions throughout the patient’s journey? By combining multiple analyses in a platform-based approach, Personalis is developing a holistic solution to managing a patient’s care including therapy selection, treatment and recurrence monitoring, all from a single specimen collected at clinical diagnosis.
In this webinar, Stephane will present:
- Example clinical use cases of a tumor-normal ctDNA assay
- Technical validation data on a variety of cancer specimens
- A future vision for comprehensive diagnostics in precision medicine
Previous registration necessary?
NO
YES
Simultaneous translation ?
NO
YES
Will it be recorded?
NO
YES
Why Oncology Needs More Than MRD
Inglês
Speakers
Stephane Mouradian
Register your event here
Already have an account? LOGIN HERE. If You don't have an account you need to create a free account.